drugset / Trial / NCT05638984
Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of low-dose decitabine combined with tirelizumab in the treatment of patients with advanced esophageal squamous cell carcinoma who did not progress in first-line immunotherapy combined with chemotherapy.
Timeline
- Start
- 2023-01-01
- Primary completion
- 2023-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg | Intravenous |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | Intravenous |
Indications
No indication recorded.